跳到正文
cccskills
免费在 GitHub 公开

ata-fludrocortisone-secondary-ai-against

Recommends against using fludrocortisone for mineralocorticoid replacement in patients with secondary adrenal insufficiency. Trigger phrases include: considering mineralocorticoid replacement for secondary adrenal insufficiency and secondary adrenal insufficiency patient needing mineralocorticoid replacement.

中文简介正在准备中。当前显示原文说明。

实测评分 未实测

查看安装方法

包含的文件(1)

  • SKILL.md2.8 KB

SKILL.md(原文)

安装前可以查看交给 AI 代理的指令内容。

Recommend against fludrocortisone use in secondary adrenal insufficiency

STEP 1 — Gather Information

Collect confirmation of secondary AI diagnosis (low morning cortisol, low/normal ACTH, subnormal response to ACTH stimulation test), assess for signs of mineralocorticoid deficiency (persistent hypotension, hyponatremia, hyperkalemia despite adequate glucocorticoid replacement), and measure plasma renin activity and aldosterone level if available. If secondary AI is confirmed and mineralocorticoid replacement is under consideration, proceed to STEP 2.

STEP 2 — Rule In / Rule Out

Is there biochemical or clinical evidence of mineralocorticoid deficiency (e.g., refractory hypotension, serum sodium <130 mmol/L, serum potassium >5.0 mmol/L, elevated plasma renin with low aldosterone) despite optimized glucocorticoid replacement? If yes, rule out secondary AI and evaluate for primary adrenal insufficiency or other causes; if no, proceed to STEP 3.

STEP 3 — Classify or Stratify

Classify the patient as having intact mineralocorticoid function (normal electrolytes, normal renin/aldosterone) versus impaired function. If mineralocorticoid function is intact, classify as no need for fludrocortisone; if impaired, consider alternative diagnoses.

STEP 4 — Decide

Do not prescribe fludrocortisone; continue glucocorticoid replacement only, educate patient on stress-dose glucocorticoids, and monitor for adrenal crisis.

Clinical Guardrails / Mimics / Pitfalls

Do not mistake secondary AI for primary AI; fludrocortisone can cause hypertension, hypokalemia, and edema in secondary AI due to intact renin-angiotensin-aldosterone system; avoid routine mineralocorticoid replacement in secondary AI as it increases risk of over-treatment and cardiovascular complications; always verify glucocorticoid adequacy before attributing hypotension to mineralocorticoid deficiency.

Concrete Clinical Example

A 45-year-old woman with known secondary AI from a nonfunctioning pituitary adenoma presents with fatigue and mild hypotension on hydrocortisone 15 mg daily. Electrolytes show Na 135 mmol/L, K 4.2 mmol/L, and plasma renin is normal. She does not require fludrocortisone; her hypotension resolves with increasing hydrocortisone to 20 mg daily.

Source: Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2016-2118

评价

还没有评价。欢迎分享你的使用感受。

评论

无需登录即可发表。欢迎分享使用感受、提问,或说明在哪些环境下无法运行。

还没有评论。来写第一条吧。

提交后会立即公开。请勿填写邮箱、电话等个人信息。URL 最多 2 个。

0 / 1000 字

此表单受 reCAPTCHA 保护,适用 Google 的隐私权政策和服务条款。

同一仓库的技能

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

中文简介正在准备中。当前显示原文说明。

dromlakhani/MD2SKILL142026年10月20日 更新

查看 dromlakhani 的全部技能

报告此技能的问题